phrykt

Mesa Laboratories Inc /Co/ (MLAB): who owns it and who trades it

As of Nov 16, 2026, MLAB insiders reported 7 open-market sales worth $1.6M and 5 purchases worth $1.4M in the last 12 months, with 16% of the sale value made under pre-set 10b5-1 plans. The largest seller was John James Sullivan (Director), with $800K. 1 of the 50 famous funds we follow held it at their last quarter end.

Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.

At a glance

Who is buying and selling Mesa Laboratories

From the latest filings

Overall: more selling than buying. Famous investors mostly sold. Funds mostly bought. Insiders was close to even.

Mostly sellingEvenMostly buying

Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.

Who owns MLAB

159 funds and institutions reported MLAB shares worth $506M at the end of Q2 2026, about 92% of the company. The largest holder is Long Path Partners LP with 8.6%.

Funds and institutions (13F) 92%Everyone else 8%

10 largest owners, by share of the company

Long Path Partners LP8.6%
BlackRock, Inc.8.0%
Boston Partners4.8%
Vanguard Capital Management LLC4.3%
AQR Capital Management LLC3.7%
Ranger Investment Management, L.P.3.1%
Morgan Stanley2.8%
Diamond Hill Capital Management, LLC (Investment Advisor)2.8%
Raymond James Financial Inc2.7%
Dimensional Fund Advisors LP2.7%

Top 20 owners

OwnerShares% of companyValueChange since Q1 2026
Long Path Partners LP477,1268.64%$47.5M+18%
BlackRock, Inc.440,5527.97%$43.9M+12%
Boston Partners265,1494.80%$26.4M-1%
Vanguard Capital Management LLC237,4574.30%$23.6M+2%
AQR Capital Management LLC203,7393.69%$20.3M+19%
Ranger Investment Management, L.P.173,9883.15%$17.3M-14%
Morgan Stanley156,9792.84%$15.6M-3%
Diamond Hill Capital Management, LLC (Investment Advisor)155,7712.82%$15.5M+0%
Raymond James Financial Inc149,9372.71%$14.9M+22%
Dimensional Fund Advisors LP148,3952.69%$14.8M+19%
Geode Capital Management, LLC139,6822.53%$13.9M+9%
Kennedy Capital Management LLC138,3012.50%$13.8M-3%
Jacobs Levy Equity Management, Inc130,8382.37%$13M+195%
State Street Corp124,2922.25%$12.4M+2%
Russell Investments Group, Ltd.121,8452.21%$12.1M-10%
Wasatch Advisors LP115,6682.09%$11.5M+126%
Royce & Associates LP113,3952.05%$11.3M-30%
Crawford Investment Counsel Inc98,8051.79%$9.8M+3%
FMR LLC (Fidelity)88,8571.61%$8.8M+1273%
D. E. Shaw & Co., Inc.81,7551.48%$8.1M+50%

From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.

Insider trades

In the last 12 months, MLAB insiders reported $1.4M of open-market purchases and $1.6M of sales. 16% of the sale value was under a 10b5-1 plan, a schedule set up in advance.

Purchases, 12 months
$1.4M
5 trades, 4 people
Sales, 12 months
$1.6M
7 trades, 4 people
Sales under a 10b5-1 plan
16%
Share of sale value
Latest trade
Aug 13, 2026
Filed Aug 17, 2026

Purchases and sales by month

$902K$902KDecFebAprJunAugOct
Purchases Sales Click a bar to show only that month below

Latest trades

DateInsiderRoleTypeSharesPriceValueFiling
Aug 13, 2026John James SullivanDirectorSale7,093$112.80$800KForm 4
Aug 13, 2026Siddhartha KadiaCEOPurchase7,093$112.80$800KForm 4
Aug 13, 2026R Tony TripenyDirectorPurchase900$113.69$102KForm 4
Jun 22, 2026Lyndsey Elizabeth CrennenCAOSale442$89.50$39.6KForm 4
Jun 22, 2026Brian David ArchboldVice presidentSale2,516$89.50$225KForm 4
Jun 22, 2026John SakysCFOSale2,827$89.50$253KForm 4
Jun 16, 2026Brian David ArchboldVice presidentSale plan1,151$101.27$117KForm 4
Jun 16, 2026Lyndsey Elizabeth CrennenCAOSale plan118$101.27$11.9KForm 4
Jun 16, 2026John SakysCFOSale plan1,223$101.27$124KForm 4
Mar 10, 2026Shiraz Shabanali LadiwalaDirectorPurchase3,500$72.23$253KForm 4
Mar 10, 2026Mark Christopher CaponeDirectorPurchase1,301$76.35$99.3KForm 4
Mar 10, 2026R Tony TripenyDirectorPurchase1,315$76.00$99.9KForm 4

Insiders by value traded

InsiderRoleBoughtSoldLast trade
John James SullivanDirector–$800KAug 13, 2026
Siddhartha KadiaPresident and CEO$800K–Aug 13, 2026
John SakysCFO–$377KJun 22, 2026
Brian David ArchboldSVP Operations–$342KJun 22, 2026
Shiraz Shabanali LadiwalaDirector$253K–Mar 10, 2026
R Tony TripenyDirector$202K–Aug 13, 2026
Mark Christopher CaponeDirector$99.3K–Mar 10, 2026
Lyndsey Elizabeth CrennenCAO–$51.5KJun 22, 2026
What this data shows, and what it doesn't
  • Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
  • Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
  • "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
  • Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
  • Filings are self-reported and can be amended. Each trade links to its original filing. Methodology

MLAB short interest

Moderate short interest. 6.7% of MLAB shares are sold short: about 1 share in 15. Over the last 12 reports the number of shares short went up 62%.

As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.

0%5%10%15%20%+

As of Oct 30, 2026, 377,163 MLAB shares were sold short, 6.7% of the shares outstanding, down 3.4% from the report before. At the average daily volume of 80,558 shares, buying them all back would take about 4.7 trading days (days to cover).

Shares short, % of all shares

6.74%May 15Oct 308.56%

Days to cover

4.7May 15Oct 305.2

Every report

Settlement dateShares short% of sharesChangeAvg daily volumeDays to cover
Oct 30, 2026377,1636.74%-3%80,5584.7
Oct 15, 2026390,5616.98%-13%102,0443.8
Sep 30, 2026447,0487.99%+11%120,9383.7
Sep 15, 2026403,5597.21%-7%133,8173.0
Aug 31, 2026433,9827.76%+28%159,8242.7
Aug 14, 2026337,7386.04%+4%170,0332.0
Jul 31, 2026324,1025.87%+18%129,6762.5
Jul 15, 2026274,1764.96%-1%227,0971.2
Jun 30, 2026276,1705.00%+15%208,7671.3
Jun 15, 2026239,1814.33%-15%267,7791.0
May 29, 2026279,8225.06%+21%210,6031.3
May 15, 2026232,1394.20%+17%137,9681.7

Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks

Mesa Laboratories company events

Mesa Laboratories filed 10 reports on Form 8-K in the last 12 months, 4 of them about an important change (leadership, job cuts). The latest was on Nov 9, 2026.

  1. Nov 9, 2026ResultsReleased financial results. Filing
  2. Oct 13, 2026Job cutsAnnounced job cuts or other exit costs. Filing
  3. Sep 8, 2026VoteReported shareholder vote results. Filing
  4. Aug 10, 2026ResultsReleased financial results. Filing
  5. Jul 30, 2026RulesChanged its code of ethics. Filing
  6. Jun 15, 2026LeadershipThe board of directors of Mesa Laboratories, Inc. approved the appointment of Lyndsey Crennen as the Chief Accounting Officer of the Company, effective as of her entry into the Employment Agreement described below. Filing
  7. May 27, 2026ResultsReleased financial results. Filing
  8. Mar 23, 2026LeadershipMesa Laboratories, Inc. announced the departure of Gary Owens as President and Chief Executive Officer of the Company, effective on or about April 13, 2026. Filing
  9. Mar 9, 2026LeadershipMesa Laboratories, Inc. initiated a leadership transition pursuant to which Gary Owens will depart as President and Chief Executive Officer of the Company, effective on or about April 13, 2026. Filing
  10. Feb 3, 2026ResultsReleased financial results. Filing

From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week

Mesa Laboratories financials

Famous investors that hold MLAB

1 of the 50 well-known investors we track reported holding MLAB in their latest 13F filing. The largest position is Ken Griffin's, worth $556K.

FundQuarterSharesValueOf portfolioChange
Ken Griffin · Citadel AdvisorsQ3 20264,278$556K0.0%-88%

From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.

5%+ stakes filed in the last 120 days

Anyone who owns more than 5% of a company must report it on Schedule 13D or 13G. 4 filings named MLAB in the last 120 days.

FiledHolderFormStake
Oct 27, 2026BlackRock, Inc.13G/A7.9%
Oct 27, 2026BlackRock, Inc.13G/A7.9%
Oct 9, 2026Wasatch Advisors LP13G6.9%
Oct 9, 2026Wasatch Advisors LP13G6.9%

Questions about Mesa Laboratories Inc /Co/ (MLAB) stock

Who owns the most MLAB stock?

The largest reported owner of Mesa Laboratories Inc /Co/ (MLAB) is Long Path Partners LP, with 8.6% of the company. In total, 159 funds and institutions reported holding MLAB at the end of Q2 2026, together about 92% of the shares. See the largest owners.

Are MLAB insiders buying or selling?

In the last 12 months, MLAB insiders reported 5 open-market purchases worth $1.4M and 7 sales worth $1.6M. The latest trade was on Aug 13, 2026. See every trade.

What is the short interest in MLAB?

As of Oct 30, 2026, 377,163 MLAB shares were sold short, 6.7% of the shares outstanding, down 3.4% from the report before. At the average daily volume of 80,558 shares, buying them all back would take about 4.7 trading days (days to cover). See the history.

Which famous investors hold MLAB?

1 of the 50 well-known investors we track reported MLAB in their latest 13F filing, including Ken Griffin. The largest position is worth $556K. See all holders.

Executive pay

Mesa Laboratories's chief executive was paid a total of $6.6M for the year ended Mar 31, 2026, up 1% from $6.6M the year before. In the last 12 months, Mesa Laboratories's executives and directors bought $1.4M of stock on the open market and sold $1.6M.

Chief executive, total pay$6.6MYear ended Mar 31, 2026. Salary, bonus and the value of stock and option awards when granted.
Pay "actually paid"$516KThe same year, with stock awards valued at what they were worth as they vested or at year end.
Other top executives, average$2.3MThe other officers named in the proxy statement.

From the pay versus performance table in the company's annual proxy statement (DEF 14A), as the company reported it. If the chief executive changed during the year, the company reports each person separately and this shows one of them.

Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.